Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Atrial flutter

6

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

4

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

A549

2

Beta-1 adrenergic receptor

2

Beta-2 adrenergic receptor

2

Cytochrome P450 3A4

2

HERG

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1992

2

2009

2

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

4

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Arnaud, L.-A.

2

Sanofi

2

Uloth, R.H. et al.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

CHEBI

6

EPA CompTox

6

FDA UNII

6

PUBCHEM

6

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CARDIAC THERAPY

2

BETA BLOCKING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIARRHYTHMICS, CLASS I AND III

1

BETA BLOCKING AGENTS

1

BETA BLOCKING AGENTS AND THIAZIDES

1

BETA BLOCKING AGENTS, OTHER COMBINATIONS

1

CARDIAC GLYCOSIDES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiarrhythmics, class III

1

Beta blocking agents, non-selective

1

Beta blocking agents, non-selective, and thiazides

1

Beta blocking agents, other combinations

1

Strophantus glycosides

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

3

Salts, Hydrates, Esters, etc.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Dronedarone

JQZ1L091Y2

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 2009

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4

Cytochrome P450 3A4

Inward rectifier potassium channel 2

Conditions:

Atrial fibrillation

Dronedarone is an antiarrhythmic that is FDA approved for the treatment of atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF). Dronedarone is multichannel blocker. Common adverse reacti...

ons include abdominal pain, diarrhea, indigestion, nausea, vomiting, asthenia and raised serum creatinine. Dronedarone has potentially important pharmacodynamics interactions: Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor; Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability; Beta-blockers: May provoke excessive bradycardia, Initiate with low dose and increase after ECG verification of tolerability.

SOTALOL

A6D97U294I

Export Data
Search for Structure

Status:

US Approved Rx (2003)

First approved in 1992

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Beta-2 adrenergic receptor

Beta-1 adrenergic receptor

Conditions:

Atrial fibrillation

Ventricular arrhythmia

Sotalol has both beta-adrenoreceptor blocking and cardiac action potential duration prolongation antiarrhythmic properties. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2...

-adrenergic receptors within bronchial and vascular smooth muscle. It is FDA approved for the treatment of ventricular arrhythmias, symptomatic atrial fibtillation, symptomatic atriall flutter. Common adverse reactions include bradyarrhythmia, chest pain, lightheadedness, palpitations, rash, nausea, dizziness, headache, dyspnea, fatigue. Proarrhythmic events were more common in sotalol treated patients also receiving digoxin. Sotalol should be administered with caution in conjunction with calcium blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. Patients treated with sotalol plus a catecholamine depletor should therefore be closely monitored for evidence of hypotension and/or marked bradycardia which may produce syncope.

OUABAIN

5ACL011P69

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sodium/potassium-transporting ATPase subunit alpha-1

Sodium/potassium-transporting ATPase subunit alpha-2

Sodium/potassium-transporting ATPase subunit alpha-3

Conditions:

Atrial fibrillation

Cardiac arrhythmia

There is no available information about this compound

Dronedarone hydrochloride

FA36DV299Q

Export Data
Search for Structure

Status:

US Approved Rx (2024)

First approved in 2009

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4

Cytochrome P450 3A4

Inward rectifier potassium channel 2

Conditions:

Atrial fibrillation

Dronedarone is an antiarrhythmic that is FDA approved for the treatment of atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF). Dronedarone is multichannel blocker. Common adverse reacti...

ons include abdominal pain, diarrhea, indigestion, nausea, vomiting, asthenia and raised serum creatinine. Dronedarone has potentially important pharmacodynamics interactions: Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor; Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability; Beta-blockers: May provoke excessive bradycardia, Initiate with low dose and increase after ECG verification of tolerability.

SOTALOL HYDROCHLORIDE

HEC37C70XX

Export Data
Search for Structure

Status:

US Approved Rx (2003)

First approved in 1992

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Beta-2 adrenergic receptor

Beta-1 adrenergic receptor

Conditions:

Atrial fibrillation

Ventricular arrhythmia

Sotalol has both beta-adrenoreceptor blocking and cardiac action potential duration prolongation antiarrhythmic properties. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2...

-adrenergic receptors within bronchial and vascular smooth muscle. It is FDA approved for the treatment of ventricular arrhythmias, symptomatic atrial fibtillation, symptomatic atriall flutter. Common adverse reactions include bradyarrhythmia, chest pain, lightheadedness, palpitations, rash, nausea, dizziness, headache, dyspnea, fatigue. Proarrhythmic events were more common in sotalol treated patients also receiving digoxin. Sotalol should be administered with caution in conjunction with calcium blocking drugs because of possible additive effects on atrioventricular conduction or ventricular function. Patients treated with sotalol plus a catecholamine depletor should therefore be closely monitored for evidence of hypotension and/or marked bradycardia which may produce syncope.

OUABAIN OCTAHYDRATE

1K0J875G48

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sodium/potassium-transporting ATPase subunit alpha-1

Sodium/potassium-transporting ATPase subunit alpha-2

Sodium/potassium-transporting ATPase subunit alpha-3

Conditions:

Atrial fibrillation

Cardiac arrhythmia

There is no available information about this compound

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1